1. Tenofovir alafenamide and tenofovir disoproxil fumarate deliver the same active moiety yet differ in safety. Which statement most precisely identifies the pharmacologic basis for tenofovir alafenamide's improved renal and bone profile?
A) Tenofovir alafenamide is a distinct molecule that is not metabolized to tenofovir, so it never produces tenofovir-related toxicity
B) Tenofovir alafenamide achieves higher plasma tenofovir concentrations, which paradoxically protects renal tubules through a saturation effect
C) Tenofovir alafenamide delivers tenofovir more efficiently to hepatocytes, achieving equal antiviral effect at roughly one-tenth the dose with substantially lower systemic tenofovir exposure
D) Tenofovir alafenamide is eliminated by hepatic conjugation rather than producing any active tenofovir, eliminating renal handling entirely
E) Tenofovir alafenamide and tenofovir disoproxil fumarate produce identical systemic tenofovir exposure, and the safety difference reflects only tablet excipients
ANSWER: C
Rationale:
Both agents are prodrugs of tenofovir, but tenofovir alafenamide is more stable in plasma and delivers tenofovir preferentially into hepatocytes, achieving equivalent antiviral efficacy at approximately one-tenth the dose (about 25 mg versus 300 mg) with markedly lower systemic tenofovir exposure. Because the renal tubular and bone-density toxicities of tenofovir are exposure-dependent, the reduced systemic exposure is the precise basis for the safety advantage.
Option A: Option A is incorrect because tenofovir alafenamide is indeed a tenofovir prodrug; it delivers the same active moiety and is not a toxicity-free distinct molecule.
Option B: Option B inverts the relationship: tenofovir alafenamide produces LOWER, not higher, systemic tenofovir, and higher exposure worsens rather than protects renal handling.
Option D: Option D is incorrect because tenofovir alafenamide does generate active tenofovir intracellularly and does not bypass renal handling entirely.
Option E: Option E is incorrect because the two prodrugs do not produce identical systemic exposure; the difference in systemic tenofovir levels, not excipients, drives the safety difference.
2. Among the preferred first-line nucleos(t)ide analogues for chronic hepatitis B, which description correctly distinguishes entecavir from tenofovir at the level of molecular class?
A) Entecavir is a guanosine (nucleoside) analogue that inhibits HBV reverse transcriptase, whereas tenofovir is a nucleotide analogue of adenosine monophosphate
B) Entecavir is a nucleotide analogue of adenosine monophosphate, whereas tenofovir is a guanosine nucleoside analogue
C) Entecavir is a protease inhibitor, whereas tenofovir is a polymerase inhibitor
D) Entecavir is a pyrimidine analogue, whereas tenofovir blocks viral entry at the sodium-taurocholate cotransporting polypeptide
E) Both entecavir and tenofovir are interferon-based immunomodulators rather than nucleos(t)ide analogues
ANSWER: A
Rationale:
Entecavir is a guanosine nucleoside analogue that inhibits HBV reverse transcriptase at multiple steps (priming, negative-strand reverse transcription, and positive-strand synthesis), whereas tenofovir is a nucleotide analogue of adenosine monophosphate. Both act on reverse transcriptase, but distinguishing the nucleoside-versus-nucleotide class and the purine identity is the precise recall point.
Option B: Option B reverses the two: entecavir is the guanosine nucleoside analogue and tenofovir is the adenosine-monophosphate nucleotide analogue, not the other way around.
Option C: Option C is incorrect because neither agent is a protease inhibitor; both inhibit the reverse transcriptase (polymerase).
Option D: Option D is incorrect because entecavir is a guanosine analogue, not a pyrimidine analogue, and tenofovir is not an entry inhibitor; entry blockade at the sodium-taurocholate cotransporting polypeptide describes bulevirtide.
Option E: Option E is incorrect because both are nucleos(t)ide analogues, not interferon-based immunomodulators.
3. A patient with chronic hepatitis B has documented lamivudine resistance carrying the M204V/M204I mutations. Which rescue strategy is appropriate, and what is the precise reason?
A) Switch to entecavir monotherapy, because entecavir is unaffected by lamivudine resistance mutations
B) Continue lamivudine at a higher dose, because the M204 mutations are overcome by dose escalation
C) Switch to pegylated interferon, because nucleos(t)ide analogues are uniformly ineffective once lamivudine resistance appears
D) Switch to entecavir at a reduced dose, because lower exposure restores its activity against resistant virus
E) Switch to tenofovir (tenofovir disoproxil fumarate or tenofovir alafenamide), because the M204V/M204I mutations cause cross-resistance that markedly reduces entecavir efficacy
ANSWER: E
Rationale:
The lamivudine resistance mutations M204V/M204I produce cross-resistance that substantially lowers entecavir's potency and drives entecavir resistance in roughly half of lamivudine-experienced patients over five years. Tenofovir (either prodrug) retains activity and is the appropriate rescue agent.
Option A: Option A is incorrect and is the key trap: entecavir is NOT unaffected by lamivudine resistance; its barrier collapses in that setting.
Option B: Option B is incorrect because dose escalation does not overcome M204 resistance to lamivudine.
Option C: Option C is incorrect because nucleos(t)ide analogues are not uniformly ineffective — tenofovir remains fully effective against lamivudine-resistant virus.
Option D: Option D is incorrect because reducing entecavir exposure would worsen, not restore, efficacy; lower drug levels favor resistant breakthrough.
4. When selecting pegylated interferon-alpha for chronic hepatitis B, certain baseline and on-treatment features predict a better response. Which set of predictors is correct?
A) Higher baseline HBV DNA and genotypes C and D predict the best pegylated interferon response
B) Favorable response is more likely with HBV genotypes A and B than C and D, and an on-treatment quantitative decline in hepatitis B surface antigen predicts response
C) The strongest predictor of pegylated interferon response is a low baseline alanine aminotransferase with no relationship to genotype
D) Decompensated cirrhosis predicts an enhanced pegylated interferon response and is therefore a preferred indication
E) A rising hepatitis B surface antigen titer during treatment is the principal favorable on-treatment predictor
ANSWER: B
Rationale:
Pegylated interferon response is more likely in HBV genotypes A and B than in C and D, and an on-treatment quantitative decline in hepatitis B surface antigen is a useful predictor of response. These are the established predictors that guide patient selection for finite interferon therapy.
Option A: Option A inverts the genotype relationship (A and B respond better than C and D) and overstates high baseline DNA as favorable.
Option C: Option C is incorrect because genotype is in fact a meaningful predictor, contrary to the claim of no relationship.
Option D: Option D is incorrect and dangerous: decompensated cirrhosis is a contraindication to pegylated interferon, not a favorable indication.
Option E: Option E inverts the surface-antigen relationship: a DECLINE in surface antigen, not a rise, predicts favorable response.
5. In chronic hepatitis B treatment endpoints, hepatitis B e antigen seroconversion and hepatitis B surface antigen loss are not equivalent. Which statement correctly discriminates between them?
A) Surface antigen loss is a routine annual occurrence on nucleos(t)ide analogues, while e antigen seroconversion is rare
B) e antigen seroconversion represents functional cure, whereas surface antigen loss is only an intermediate endpoint
C) Both endpoints are interchangeable terms for the same serologic event
D) e antigen seroconversion is a meaningful intermediate endpoint that can permit considering treatment discontinuation in selected non-cirrhotic patients, whereas surface antigen loss reflects functional cure and is uncommon (roughly 1 to 3 percent per year on therapy)
E) Surface antigen loss must occur before e antigen seroconversion can be achieved
ANSWER: D
Rationale:
e antigen seroconversion (loss of e antigen with development of anti-HBe) is a meaningful intermediate endpoint; after durable seroconversion, discontinuation can be considered in selected non-cirrhotic patients. Surface antigen loss reflects functional cure and remains uncommon, occurring in only about 1 to 3 percent of nucleos(t)ide-analogue-treated patients per year. Distinguishing the intermediate endpoint from functional cure is the precise recall point.
Option A: Option A inverts the frequencies: surface antigen loss is the rare event, not a routine annual occurrence.
Option B: Option B reverses the two endpoints: surface antigen loss — not e antigen seroconversion — is the functional cure.
Option C: Option C is incorrect because the two are distinct serologic events, not interchangeable.
Option E: Option E is incorrect because e antigen seroconversion typically precedes any surface antigen loss; surface antigen loss is not a prerequisite for e antigen seroconversion.
6. Sofosbuvir and the NS5A inhibitors differ markedly in their barrier to resistance. Which statement correctly captures the distinction and its molecular basis?
A) Sofosbuvir, an NS5B nucleotide chain terminator, has an exceptionally high resistance barrier because the resistance substitution S282T carries a high viral fitness cost, whereas NS5A inhibitors used alone have a comparatively low resistance barrier
B) NS5A inhibitors have the highest resistance barrier of all DAAs, while sofosbuvir resistance emerges readily within weeks
C) Both sofosbuvir and NS5A inhibitors have an equally low resistance barrier, which is why three-drug regimens are always required
D) Sofosbuvir's high resistance barrier arises from its inhibition of the NS3/4A protease, not the NS5B polymerase
E) The S282T substitution confers a fitness advantage to the virus, which is why sofosbuvir resistance is common
ANSWER: A
Rationale:
Sofosbuvir is an NS5B nucleotide chain terminator with an exceptionally high barrier to clinical resistance because the key resistance substitution, S282T, imposes a high fitness cost on the virus, making resistant variants poorly viable. NS5A inhibitors used alone have a comparatively low resistance barrier, which is why they are always combined with another class.
Option B: Option B inverts both claims: the NS5A inhibitors have the lower barrier, and sofosbuvir resistance is rare, not rapid.
Option C: Option C is incorrect because the two classes do not have equally low barriers; sofosbuvir's barrier is high.
Option D: Option D misattributes the mechanism: sofosbuvir inhibits NS5B, not the NS3/4A protease.
Option E: Option E inverts the fitness relationship: S282T carries a fitness cost (disadvantage), which is precisely why sofosbuvir resistance is uncommon.
7. The DAA classes differ in their drug-interaction liability. Which statement correctly identifies the class most associated with clinically important interactions and the basis for it?
A) The NS5B nucleotide inhibitor sofosbuvir is the principal source of cytochrome-mediated interactions because it strongly inhibits CYP3A4
B) NS5A inhibitors are the dominant source of interactions because they irreversibly inhibit all cytochrome P450 isoforms
C) The NS3/4A protease inhibitors (the "-previr" agents) carry important interactions because they are substrates and inhibitors of P-glycoprotein and CYP3A4, so strong CYP3A4 inducers can render them subtherapeutic
D) None of the DAA classes interact with cytochrome enzymes or transporters, so interaction checking is unnecessary
E) Ribavirin is the protease inhibitor responsible for the major CYP3A4 interactions in modern regimens
ANSWER: C
Rationale:
The NS3/4A protease inhibitors (the "-previr" agents such as glecaprevir, grazoprevir, and voxilaprevir) are substrates and inhibitors of P-glycoprotein and CYP3A4, giving them the most important interaction profile among the DAA classes; strong CYP3A4 inducers can reduce their levels to subtherapeutic concentrations.
Option A: Option A is incorrect because sofosbuvir is not a strong CYP3A4 inhibitor and is not the principal interaction source.
Option B: Option B is incorrect because NS5A inhibitors are not irreversible pan-CYP inhibitors; that mischaracterizes their pharmacology.
Option D: Option D is incorrect and unsafe: interaction checking is mandatory precisely because the protease inhibitor class interacts significantly.
Option E: Option E is incorrect because ribavirin is not a protease inhibitor; it is a nucleoside antiviral with a different role, and it is not the source of the CYP3A4 interactions.
8. The two first-line pan-genotypic hepatitis C regimens are sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. Which statement correctly discriminates between them with respect to renal use?
A) Sofosbuvir/velpatasvir is sofosbuvir-free and is therefore preferred in dialysis-dependent patients
B) Glecaprevir/pibrentasvir contains no sofosbuvir component and does not require dose adjustment in renal impairment, making it preferred in advanced chronic kidney disease including dialysis
C) Both regimens contain sofosbuvir, so both require dose reduction once estimated glomerular filtration rate falls below 30 mL/min/1.73m2
D) Glecaprevir/pibrentasvir contains sofosbuvir, whose renal metabolite accumulates and improves efficacy in kidney disease
E) Sofosbuvir/velpatasvir requires no renal consideration because sofosbuvir is cleared entirely by hepatic metabolism
ANSWER: B
Rationale:
Glecaprevir/pibrentasvir combines an NS3/4A inhibitor with an NS5A inhibitor and contains no sofosbuvir. It does not require dose adjustment in renal impairment and is the preferred pan-genotypic regimen in advanced chronic kidney disease, including dialysis. Sofosbuvir/velpatasvir, by contrast, contains sofosbuvir, whose inactive metabolite accumulates in severe renal impairment.
Option A: Option A is incorrect because sofosbuvir/velpatasvir DOES contain sofosbuvir; it is not the sofosbuvir-free option.
Option C: Option C is incorrect because the two regimens are not both sofosbuvir-containing; glecaprevir/pibrentasvir has no sofosbuvir.
Option D: Option D is incorrect on two counts: glecaprevir/pibrentasvir does not contain sofosbuvir, and sofosbuvir metabolite accumulation is a liability in renal impairment, not an efficacy benefit.
Option E: Option E is incorrect because sofosbuvir is eliminated renally (as the metabolite GS-331007), not entirely by hepatic metabolism, so renal function is relevant to sofosbuvir-containing regimens.
9. The three-class regimen sofosbuvir/velpatasvir/voxilaprevir occupies a specific niche distinct from the two first-line pan-genotypic regimens. Which statement correctly identifies its role?
A) It is the preferred initial regimen for all treatment-naive non-cirrhotic patients
B) It is used only in acute, never chronic, hepatitis C infection
C) It is reserved for patients with decompensated cirrhosis because the added protease inhibitor is hepatoprotective
D) It is a first-line option specifically because it shortens treatment to four weeks in naive patients
E) It is reserved largely for treatment-experienced patients, including those who failed prior DAA therapy or have genotype 3 with baseline NS5A resistance-associated substitutions
ANSWER: E
Rationale:
Sofosbuvir/velpatasvir/voxilaprevir adds a protease inhibitor to the sofosbuvir/velpatasvir backbone and is reserved largely for treatment-experienced patients — particularly those who have failed prior DAA therapy or who have genotype 3 with baseline NS5A resistance-associated substitutions — rather than as initial therapy.
Option A: Option A is incorrect because it is not the preferred regimen for treatment-naive patients; the two first-line pan-genotypic regimens fill that role.
Option B: Option B is incorrect because its use is not restricted to acute infection.
Option C: Option C is incorrect and unsafe: protease inhibitor-containing regimens are not hepatoprotective in decompensated cirrhosis — protease inhibitors are generally avoided in decompensated disease.
Option D: Option D is incorrect because its niche is salvage of treatment-experienced patients, not a four-week naive-patient course.
10. Two distinct co-medication hazards arise with DAA therapy: one with amiodarone and one with rifampin. Which statement correctly distinguishes the mechanism and consequence of each?
A) Amiodarone induces CYP3A4 and lowers DAA levels, while rifampin causes symptomatic bradycardia with sofosbuvir
B) Both amiodarone and rifampin cause the same effect — severe bradycardia — through identical mechanisms
C) Amiodarone raises DAA levels by inhibiting P-glycoprotein, while rifampin causes hepatotoxicity from glutathione depletion
D) Amiodarone with a sofosbuvir-containing regimen risks serious, potentially fatal symptomatic bradycardia, whereas rifampin, a strong CYP3A4 and P-glycoprotein inducer, lowers DAA levels to subtherapeutic concentrations
E) Neither combination is clinically significant; both can be co-administered without precaution
ANSWER: D
Rationale:
These are two separate hazards. Amiodarone combined with a sofosbuvir-containing regimen risks serious, potentially fatal symptomatic bradycardia and is contraindicated unless no alternative exists with cardiac monitoring. Rifampin, a strong inducer of CYP3A4 and P-glycoprotein, lowers DAA plasma concentrations to subtherapeutic levels and is an absolute contraindication with protease inhibitor-containing regimens.
Option A: Option A is incorrect because it swaps the two: amiodarone is the bradycardia hazard and rifampin is the inducer, not the reverse.
Option B: Option B is incorrect because the two have different mechanisms and different consequences, not identical ones.
Option C: Option C is incorrect because amiodarone's hazard is bradycardia (not P-glycoprotein-mediated level elevation) and rifampin's hazard is induction (not glutathione-depletion hepatotoxicity, which belongs to acetaminophen).
Option E: Option E is incorrect and unsafe because both combinations are clinically significant and require precaution or avoidance.
11. A patient on a statin is starting glecaprevir/pibrentasvir for hepatitis C. Which statement correctly describes the relevant statin interaction?
A) Rosuvastatin is contraindicated with glecaprevir/pibrentasvir, and atorvastatin requires dose capping, because the protease inhibitor raises statin exposure via inhibition of CYP3A4 and the OATP1B transporter
B) Statins have no interaction with any DAA regimen and may be continued unchanged
C) Glecaprevir/pibrentasvir lowers statin levels, so the statin dose must be increased to maintain effect
D) All statins are absolutely safe with glecaprevir/pibrentasvir except pravastatin, which is contraindicated
E) The interaction occurs only with sofosbuvir and never with protease inhibitor-containing regimens
ANSWER: A
Rationale:
NS3/4A protease inhibitors raise statin exposure through inhibition of CYP3A4 and the hepatic uptake transporter OATP1B, increasing myopathy risk. With glecaprevir/pibrentasvir, rosuvastatin is contraindicated and atorvastatin requires dose capping.
Option B: Option B is incorrect because a clinically important statin interaction does exist with protease inhibitor-containing regimens.
Option C: Option C inverts the direction: the regimen raises, not lowers, statin levels, so the dose is reduced or the statin avoided, not increased.
Option D: Option D misidentifies the affected agents — rosuvastatin (not pravastatin) is the contraindicated statin in this setting.
Option E: Option E is incorrect because the interaction is driven by the protease inhibitor component, the opposite of the claim that it occurs only with sofosbuvir.
12. Bulevirtide for hepatitis D produces a characteristic laboratory change during treatment. Which statement correctly pairs its mechanism with the expected finding?
A) By inhibiting intracellular HDV polymerase, bulevirtide causes a rapid fall in HDV RNA within 48 hours and a drop in serum bile acids
B) By inducing interferon-stimulated genes, bulevirtide causes flu-like symptoms and marrow suppression as its principal laboratory signature
C) By competitively blocking the sodium-taurocholate cotransporting polypeptide, bulevirtide reduces hepatocyte bile acid uptake, producing a dose-dependent rise in serum conjugated bile acids that is pharmacodynamic rather than hepatotoxic
D) By depleting glutathione, bulevirtide raises serum aminotransferases as a marker of direct hepatocyte necrosis
E) By blocking the surface antigen, bulevirtide lowers serum conjugated bile acids and shortens its own time to virologic effect
ANSWER: C
Rationale:
Bulevirtide competitively blocks the sodium-taurocholate cotransporting polypeptide, the receptor for both viral entry and hepatocyte bile acid uptake. Blocking it reduces bile acid uptake, producing a dose-dependent rise in serum conjugated bile acids that is a pharmacodynamic marker of target engagement rather than a sign of hepatotoxicity, and does not usually require discontinuation.
Option A: Option A is incorrect because bulevirtide blocks entry rather than intracellular polymerase, so its virologic effect is delayed, not rapid, and bile acids rise rather than fall.
Option B: Option B describes pegylated interferon's mechanism and adverse profile, not bulevirtide's.
Option D: Option D is incorrect because glutathione depletion is the acetaminophen mechanism, and the bile acid rise with bulevirtide is not a necrosis marker.
Option E: Option E is incorrect because bulevirtide does not act on the surface antigen, and it raises rather than lowers conjugated bile acids; its effect is delayed, not shortened.
13. In a patient with hepatitis D superinfection on a chronic hepatitis B background, what is the correct role of nucleos(t)ide analogue therapy?
A) Nucleos(t)ide analogues directly and potently suppress HDV RNA and are sufficient as sole therapy for hepatitis D
B) Nucleos(t)ide analogue therapy does not meaningfully suppress HDV RNA on its own, but it is indicated to control concurrent HBV replication and protect the liver, and by suppressing HBV it reduces the surface antigen substrate available for HDV virion production
C) Nucleos(t)ide analogues are contraindicated in hepatitis D because they accelerate HDV replication
D) Nucleos(t)ide analogues cure hepatitis D by eliminating the cccDNA that HDV requires
E) Nucleos(t)ide analogues are interchangeable with bulevirtide and provide identical anti-HDV effect
ANSWER: B
Rationale:
Nucleos(t)ide analogues do not meaningfully suppress HDV RNA by themselves, but they are indicated to control concurrent HBV replication and protect the liver; because HDV depends on hepatitis B surface antigen for assembly, suppressing HBV reduces the surface antigen substrate available for HDV virion production, which is why nucleos(t)ide analogues are recommended as background therapy.
Option A: Option A is incorrect because nucleos(t)ide analogues do not directly suppress HDV RNA and are not sufficient as sole anti-HDV therapy.
Option C: Option C is incorrect because they are not contraindicated and do not accelerate HDV replication.
Option D: Option D is incorrect because nucleos(t)ide analogues do not eliminate cccDNA and do not cure hepatitis D.
Option E: Option E is incorrect because they are not interchangeable with bulevirtide; bulevirtide is the entry inhibitor with direct anti-HDV activity, whereas nucleos(t)ide analogues serve as HBV-directed background therapy.
14. Regarding the standard intravenous N-acetylcysteine regimen for acetaminophen poisoning, which statement is correct?
A) N-acetylcysteine acts by directly binding circulating acetaminophen and is dosed as a single fixed 5-gram bolus regardless of weight
B) The regimen works by inhibiting CYP2E1 and is most effective when started only after 24 hours
C) N-acetylcysteine is dosed to a fixed serum concentration target measured hourly, independent of body weight
D) The standard intravenous regimen is a weight-based three-bag protocol (150 mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, totaling 300 mg/kg over 21 hours), and it works by supplying cysteine to replenish glutathione, with greatest benefit when started early
E) N-acetylcysteine is given as a single oral dose because intravenous administration offers no advantage and the oral route is always preferred even in encephalopathic patients
ANSWER: D
Rationale:
The standard intravenous N-acetylcysteine protocol is a weight-based three-bag regimen — 150 mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, totaling 300 mg/kg over 21 hours — and it works by providing cysteine, the rate-limiting substrate for glutathione synthesis, with the greatest benefit when started early in the course.
Option A: Option A is incorrect because the drug acts by glutathione repletion rather than directly binding acetaminophen, and dosing is weight-based and multiphasic, not a single fixed bolus.
Option B: Option B is incorrect because the mechanism is glutathione repletion, not CYP2E1 inhibition, and efficacy is greatest early rather than only after 24 hours.
Option C: Option C is incorrect because dosing is weight-based by protocol, not titrated to an hourly serum concentration target.
Option E: Option E is incorrect because intravenous administration is standard, and oral loading is specifically avoided in encephalopathic patients because of aspiration risk.
15. The King's College Criteria use different parameters depending on the cause of acute liver failure. Which option correctly distinguishes the acetaminophen criteria from the non-acetaminophen criteria?
A) For acetaminophen-induced disease, arterial pH below 7.30 after resuscitation (or the triad of creatinine above 3.4 mg/dL, prothrombin time above 100 seconds, and grade III-IV encephalopathy) identifies high risk; for non-acetaminophen disease, a prothrombin time above 100 seconds alone, or a combination of age, etiology, jaundice-to-encephalopathy interval, prothrombin time, and bilirubin, is used
B) Both etiologies use an identical single threshold: serum bilirubin above 17.5 mg/dL
C) The acetaminophen criteria rely solely on serum acetaminophen level, while the non-acetaminophen criteria rely solely on viral serologies
D) For acetaminophen disease the criterion is an arterial pH above 7.50, reflecting alkalosis from hyperventilation
E) The non-acetaminophen criteria require a normal prothrombin time, since coagulopathy excludes the diagnosis
ANSWER: A
Rationale:
The King's College Criteria differ by etiology. For acetaminophen-induced acute liver failure, high risk is identified by arterial pH below 7.30 after resuscitation, or by all three of serum creatinine above 3.4 mg/dL, prothrombin time above 100 seconds, and grade III-IV encephalopathy. For non-acetaminophen disease, a prothrombin time above 100 seconds alone, or any three of a set including age, etiology, jaundice-to-encephalopathy interval, prothrombin time, and bilirubin, is used.
Option B: Option B is incorrect because the two etiologies do not share a single identical bilirubin threshold; bilirubin is only one element of the non-acetaminophen set.
Option C: Option C is incorrect because the criteria are prognostic clinical and laboratory parameters, not a sole acetaminophen level or sole viral serology.
Option D: Option D inverts the acetaminophen acid-base criterion: the threshold is a low pH (below 7.30), reflecting acidosis, not an alkalotic pH above 7.50.
Option E: Option E is incorrect because coagulopathy (a prolonged prothrombin time) is central to the non-acetaminophen criteria, not an exclusion.
16. In the intensive care management of acute liver failure, which statement correctly identifies first-line pharmacologic approaches and distinguishes them from interventions of limited or unproven benefit?
A) Lactulose dosed to aggressive catharsis is the proven first-line measure that reduces mortality in acute liver failure
B) Dopamine is the preferred first-line vasopressor for the vasodilatory shock of acute liver failure, and norepinephrine should be avoided
C) Cerebral edema is best managed by withholding all osmotherapy and permitting hypernatremia to resolve spontaneously
D) Stress ulcer prophylaxis should be withheld because acid suppression precipitates encephalopathy
E) Cerebral edema and intracranial hypertension are managed with osmotherapy (mannitol for intracranial pressure crises, hypertonic saline as prophylaxis targeting mild hypernatremia), and norepinephrine is the first-line vasopressor; lactulose has limited evidence in acute liver failure and should be titrated to a few soft stools rather than catharsis
ANSWER: E
Rationale:
In acute liver failure, cerebral edema and intracranial hypertension are leading causes of death and are managed with osmotherapy — mannitol for intracranial pressure crises and hypertonic saline as prophylaxis, targeting a mildly elevated serum sodium. Norepinephrine is the first-line vasopressor for the vasodilated, high-output hemodynamic profile. Lactulose has limited evidence in acute liver failure and should be titrated to a few soft stools rather than aggressive catharsis, which can cause bowel distension that impairs surgical access.
Option A: Option A is incorrect because lactulose is not a proven mortality-reducing first-line measure in acute liver failure and aggressive catharsis is harmful.
Option B: Option B inverts the vasopressor choice: norepinephrine, not dopamine, is first-line.
Option C: Option C is incorrect because osmotherapy is a mainstay of cerebral edema management, not something to withhold.
Option D: Option D is incorrect because stress ulcer prophylaxis is standard, not contraindicated, in acute liver failure.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.